Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Common Equity: 2024

Historic Common Equity for Pharming Group N.V (PHAR) over the last 1 years, with Dec 2024 value amounting to $221.1 million.

  • Pharming Group N.V's Common Equity rose 81.82% to -$4 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4, marking a year-over-year increase of 81.82%. This contributed to the annual value of $221.1 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Pharming Group N.V reported Common Equity of $221.1 million as of FY2024.
  • Pharming Group N.V's 5-year Common Equity high stood at $221.1 million for FY2024, and its period low was $221.1 million during FY2024.
  • Its 1-year average for Common Equity is $221.1 million, with a median of $221.1 million in 2024.